News Feed Opinion Career Insight Dialogues Blog Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
August, 2024
August 2024
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Most cancer drugs granted accelerated approval did not demonstrate benefit in overall survival – JAMA Oncology
Photo from JAMA Oncology/X
Apr 11, 2024, 12:58

Most cancer drugs granted accelerated approval did not demonstrate benefit in overall survival – JAMA Oncology

JAMA Oncology shared on X/Twitter:

“Most cancer drugs granted accelerated approval did not demonstrate benefit in overall survival or quality of life within 5 years of accelerated approval.”

Visit the article website.
Source: JAMA Oncology/X

approval cancer cancer drugs JAMA Oncology OncoDaily Oncology
Insight
Aug 27, 2024, 03:50
Jose Debes: Right attitude to fight HPB cancers in Africa
Insight
Aug 27, 2024, 03:39
Shuchi Gulati: Sumanta K. Pal on the role of gut microbiome to optimize immunotherapy in cancer at CCCC24
Insight
Aug 27, 2024, 03:36
SIO - ASCO guidelines for treatment of common cancer symptoms
Insight
Aug 27, 2024, 03:29
David Lee: Awesome to be the host country for ESTRO meets Asia 2024
Insight
Aug 27, 2024, 03:25
Daniel Castellano: HABEMUS ESMO football 2024 tournament
Insight
Aug 27, 2024, 03:21
An open letter to policy makers: Effects of the climate crisis on cancer
Insight
Aug 27, 2024, 03:17
Understanding how cells communicate both spatially and temporally in an article by Liu et al.
Blog
Aug 27, 2024, 03:14
Sendurai Mani: How Monkeys Taught Me About Responsibility and Looking Beyond the Obvious
Insight
Aug 27, 2024, 03:11
Castalia Fernández: The molecular era of treatment of gliomas
Insight
Aug 27, 2024, 03:05
Ashish M. Kamat: Bladder-sparing Therapy for BCG–unresponsive NMIBC
Insight
Aug 27, 2024, 02:59
Anne Knisely: Metronidazole and Cefazolin for SSI prophylaxis in gynaecological surgery
Blog
Aug 26, 2024, 21:44
Tanja Obradovic: Can we expect new EGFR TKI to surpass osimertinib in primary tumor and intracranial progression of NSCLC